{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"Auto-HCT only"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"}],"units":"Participants"}],"title":"Auto-HCT then Allo-HCT"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"}],"units":"Participants"}],"title":"All Participants"}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"}],"units":"Participants"}],"description":"Event-free survival (EFS) as determined for all participants who received the initial Auto-HCT treatment. \"Event\" was defined as any of the following within 3 years of the participant's last infusion of Auto-HCT or Allo-HCT: relapse; death; or last follow-up if there is no data to document the participant remained alive at 3 years.","groups":[{"description":"Auto-HCT mobilization is cyclophosphamide 4 g/m2 + filgrastim 10 µg/kg/day for peripheral blood progenitor cell (PBPC) collection by apheresis. Transplant conditioning is high-dose melphalan 200 mg/m2, followed by PBPC infusion as melphalan rescue \\[ie, autologous hematopoietic cells transplant (Auto-HCT)\\]. Post-infusion support is filgrastim 5 µg/kg/day, starting 6 days after melphalan. Stable/responsive disease at 4 weeks continues to allogenic HCT (Allo-HCT) from sibling donor fully-matched for human leukocyte antigen (HLA). Allo-HCT conditioning is total body irradiation (TBI) 200 centigray (cGy) + cyclosporine (CSP) 6.25 mg/kg + mycophenolate mofetil (MMF) 15 mg/kg. Donor mobilization is filgrastim 16 µg/kg/day on day -4 to Day 0; apheresis collections on Day -1 \\& Day 0, to a target of \\> 5 x 10e6 CD34 cells/kg. Allo-HCT is infused to participant on Day 0, with premedication hydrocortisone 100 mg IV \\& diphenhydramine 50 mg IV. CSP tapering on Day 56 to Day 180, adjusted as needed.","id":"OG000","title":"Auto- Then Allo-HCT"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The outcome data are reported as the number of participants who do not experience an EFS event within 3 years from the date of the last transplant, for the \"Auto-HCT only\" population, the \"Auto-HCT then Allo-HCT\" population, and the overall study population (ie, \"Auto-HCT only\" plus +\"Auto-HCT then Allo-HCT\").","reportingStatus":"POSTED","timeFrame":"3 years","title":"Event-free Survival (EFS)","type":"PRIMARY","unitOfMeasure":"Participants"}